Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Solange Peters; Urania Dafni; Michael Boyer; Dirk De Ruysscher; Corinne Faivre-Finn; Enriqueta Felip; Pilar Garrido; Nicolas Girard; Matthias Guckenberger; John Haanen; Cecile Le Pechoux; Francoise Mornex; Mahmut Ozsahin; Luis Paz-Ares; David Planchard; David Raben; Suresh Ramalingam; Martin Reck; Egbert Smit; Rolf Stahel; Albrecht Stenzinger; Charlie Swanton; Stefania Vallone; Marina Garassino

doi:10.1093/annonc/mdy553

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Solange Peters, Urania Dafni, Michael Boyer, Dirk De Ruysscher, Corinne Faivre-Finn, Enriqueta Felip, Pilar Garrido, Nicolas Girard, Matthias Guckenberger, John Haanen, Cecile Le Pechoux, Francoise Mornex, Mahmut Ozsahin, Luis Paz-Ares, David Planchard, David Raben, Suresh Ramalingam, Martin Reck, Egbert Smit, Rolf StahelAlbrecht Stenzinger, Charlie Swanton, Stefania Vallone, Marina Garassino

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
DOIs	https://doi.org/10.1093/annonc/mdy553
Publication status	Published - 8 Jan 2019

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdy553

Our research as part of the international PACIFIC trial, led to the approval of a new treatment (Durvalumab) which improves progression free and overall survival in Stage III Non-small cell lung cancer (NSCLC)
Faivre-Finn, C. (Corresponding participant)
Impact: Health and wellbeing

Cite this

Peters, S., Dafni, U., Boyer, M., De Ruysscher, D., Faivre-Finn, C., Felip, E., Garrido, P., Girard, N., Guckenberger, M., Haanen, J., Le Pechoux, C., Mornex, F., Ozsahin, M., Paz-Ares, L., Planchard, D., Raben, D., Ramalingam, S., Reck, M., Smit, E., ... Garassino, M. (2019). Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1093/annonc/mdy553

@article{a1680fbc81d549e889f5fc5606b018ec,

title = "Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)",

author = "Solange Peters and Urania Dafni and Michael Boyer and {De Ruysscher}, Dirk and Corinne Faivre-Finn and Enriqueta Felip and Pilar Garrido and Nicolas Girard and Matthias Guckenberger and John Haanen and {Le Pechoux}, Cecile and Francoise Mornex and Mahmut Ozsahin and Luis Paz-Ares and David Planchard and David Raben and Suresh Ramalingam and Martin Reck and Egbert Smit and Rolf Stahel and Albrecht Stenzinger and Charlie Swanton and Stefania Vallone and Marina Garassino",

year = "2019",

month = jan,

day = "8",

doi = "10.1093/annonc/mdy553",

language = "English",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

}

Peters, S, Dafni, U, Boyer, M, De Ruysscher, D, Faivre-Finn, C, Felip, E, Garrido, P, Girard, N, Guckenberger, M, Haanen, J, Le Pechoux, C, Mornex, F, Ozsahin, M, Paz-Ares, L, Planchard, D, Raben, D, Ramalingam, S, Reck, M, Smit, E, Stahel, R, Stenzinger, A, Swanton, C, Vallone, S & Garassino, M 2019, 'Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)', Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1093/annonc/mdy553

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). / Peters, Solange; Dafni, Urania; Boyer, Michael et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, 08.01.2019.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

AU - Peters, Solange

AU - Dafni, Urania

AU - Boyer, Michael

AU - De Ruysscher, Dirk

AU - Faivre-Finn, Corinne

AU - Felip, Enriqueta

AU - Garrido, Pilar

AU - Girard, Nicolas

AU - Guckenberger, Matthias

AU - Haanen, John

AU - Le Pechoux, Cecile

AU - Mornex, Francoise

AU - Ozsahin, Mahmut

AU - Paz-Ares, Luis

AU - Planchard, David

AU - Raben, David

AU - Ramalingam, Suresh

AU - Reck, Martin

AU - Smit, Egbert

AU - Stahel, Rolf

AU - Stenzinger, Albrecht

AU - Swanton, Charlie

AU - Vallone, Stefania

AU - Garassino, Marina

PY - 2019/1/8

Y1 - 2019/1/8

U2 - 10.1093/annonc/mdy553

DO - 10.1093/annonc/mdy553

M3 - Article

C2 - 30624547

SN - 0923-7534

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E et al. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Jan 8. doi: 10.1093/annonc/mdy553

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Impacts

Our research as part of the international PACIFIC trial, led to the approval of a new treatment (Durvalumab) which improves progression free and overall survival in Stage III Non-small cell lung cancer (NSCLC)

Cite this